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INTRODUCTION
Acute pancreatitis is an inflammatory disease resulting
from the autoactivation of digestive enzymes in the pancre-
atic acinar cell. Inflammatory cell recruitment, proinflam-
matory cytokines, and oxygen-derived free radicals have been
reported to play an important role in determining the sever-
ity of acute pancreatitis (1-4). Exposure of many tissues and
cells to proinflammatory cytokines results in the expression
of the inducible isoform nitric oxide synthase (iNOS) (5). An
enhanced formation of nitric oxide (NO) due to the induction
of iNOS has been implicated in the pathogenesis of shock
and inflammation (6). Al-Mufti et al. (7) reported that excess
NO arising from the iNOS is an important factor underly-
ing the systemic and local hemodynamic disturbances and
oxidative tissue damage associated with acute pancreatitis.
Furthermore, iNOS-deficient mice have been shown to exhib-
it resistance to the acute pancreatitis induced by cerulein (8).
Therefore, production of NO by iNOS has been proposed as
a pathogenic factor in acute pancreatitis. 
NO is an inorganic, gaseous free radical that is involved
in the physiology of circulation and in pathophysiologic con-
ditions such as inflammation. NO is synthesized from the
amino acid L-arginine by a family of enzymes, the NOS (9,
10). To date three isoforms of NOS have been identified: two
of them are termed neuronal constitutive (nNOS or NOS-1)
and endothelial constitutive (eNOS or NOS-3), which are
constantly present and synthesize small amounts of NO in
response to physical or receptor stimulation. The inducible
NOS (iNOS or NOS-2), the third NO isoform, is found only
after stimuli such as endotoxin or proinflammatory cytokines
and generates large amounts of NO in a sustained and large-
ly uncontrolled manner (5, 10-12). 
Excess production of NO causes vasodilatation and hypo-
tension that is refractory to vasoconstriction, together with
increased microvascular permeability and extravascular third
spacing (9). Moreover, NO rapidly reacts with the superoxide
anion, which results in the formation of peroxynitrate and
hydroxyl radicals, both powerful oxidants and cytotoxic agents
(13). These findings suggest that the overproduction of NO
by iNOS plays an important role in the hemodynamic dis-
turbances and cellular damage of several inflammatory states.
Several investigators have examined the role of NO in vari-
ous animal models of acute pancreatitis (14-25). However,
conflicting results have been reported. There are several lines
of evidence showing that NO seems to have a protective effect
on local pancreatic cellular damage, mainly by inhibition of
neutrophil accumulation and improvement of microcircula-
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The Role of Nitric Oxide in Experimental Cerulein Induced Pancreatitis
An enhanced formation of nitric oxide (NO), due to the induction of inducible nitric
oxide synthase (iNOS), has been implicated in the pathogenesis of shock and inflam-
mation, but its role in acute pancreatitis still remains controversial. To clarify the role
of NO in acute pancreatitis, the present experiment investigated the expression
of iNOS and the effect of NOS inhibition on cerulein-induced pancreatitis in rats.
Group I received intraperitoneal (ip) injection of normal saline. Group II received
two ip injections of cerulein (20  g/kg). Group III received injections of N
G-nitro-
L-arginine methyl ester (L-NAME) (30 mg/kg) with cerulein. Group IV received L-
arginine (250 mg/kg) with cerulein and L-NAME. The expression of iNOS in the
pancreas was examined by western blot analysis. The plasma concentration of
NO metabolites was measured. The severity of pancreatitis was assessed by mea-
suring serum amylase, pancreas water content and histopathological examination.
Compared with controls, the cerulein group displayed significantly increased expres-
sion of iNOS and raised plasma NO metabolites. Treatment with L-NAME signif-
icantly decreased hyperamylasemia, plasma NO level, and the extent of pancre-
atic injury. Treatment with L-arginine reversed the effects of L-NAME. These find-
ings suggest that an enhanced formation of NO by iNOS plays an important role
in the development of acute pancreatitis, and inhibition of NO production has the
beneficial effects in reducing pancreas injury.
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tion (14-19). In contrast, several reports suggest that inhibi-
tion of NOS or iNOS has a beneficial effect in experimental
pancreatitis (20-25). 
To clarify the role of NO in acute pancreatitis, we exam-
ined the expression of iNOS and the effects of NOS inhibi-
tion on cerulein-induced pancreatitis in rats.
MATERIALS AND METHODS
Animals
Male Sprague-Dawley rats (200-250 g) were used. All rats
were fed standard laboratory chow diet (Cheil-jedang Co.,
Seoul, Korea) and housed in 12 hr dark-light rooms under
controlled temperature (23±1℃) and humidity (65%). All
experiments were performed according to protocols approved
by the Korea University Hospital Animal Research Com-
mittee, and maintained in accordance with the Guidelines
for the Care and Use of Laboratory Animals of Korea Uni-
versity. 
Experimental Protocol 
Forty rats were randomly divided into four groups of 10
animals each, and subjected to the treatment regimens list
below. Group I (control) received four intraperitoneal injec-
tion of normal saline at 1 hr intervals. Group II (cerulein)
received two intraperitoneal injection of cerulein (Research
Plus, Bayonne, NJ, U.S.A.) at a dose of 20  g/kg body weight
at 1 hr intervals. Group III (cerulein+L-NAME) received
two intraperitoneal injections of cerulein at l hr intervals
and four intraperitoneal injections of N
G-nitro-L-arginine
methyl ester (L-NAME, Sigma Chemical Co., St. Louis, MO,
U.S.A.) at a dose of 30 mg/kg body weight at 1 hr intervals.
First injection of L-NAME started with the first cerulein
injection. Group IV (cerulein+L-NAME+L-arginine) received
cerulein and L-NAME, as in group III and received two intra-
venous injection of L-arginine (Sigma Chemical Co.) at a dose
of 250 mg/kg body weight as a bolus into the tail vein at 1
hr intervals simultaneously with cerulein and L-NAME. 
Five hours after initiation of the cerulein or physiologic
saline injection, the rats were anesthetized with an intraperi-
toneal injection of sodium pentobarbital (Sigma Chemical
Co.), a dose of 40 mg/kg body weight. Before killing the
rats, the blood was collected from the abdominal aorta to
assay serum amylase, plasma NOx (NO2 plus NO3). All blood
samples were centrifuged at 1,800 rpm for 10 min at 4℃.
The plasma was sampled using sterile pipettes. These sam-
ples were then immediately stored at -70℃ until assayed.
After killing the rats, the pancreas was quickly removed and
small pieces of the pancreas were excised for routine histo-
logical examination. The remainder of each pancreas was
stored at -70℃for western blot analysis of iNOS. 
Amylase and NOx Assay
Serum amylase was measured by an enzymatic assay, using
the Abbott spectrum analyzer (Abbott, Chicago, IL, U.S.A.).
Measurements of plasma NOx concentration were deter-
mined by Griess reaction (26) using nitrate/nitrite colori-
metric assay kit (Cayman, Ann Arbor, MI, U.S.A.) 
Western Blot Analysis of iNOS 
Pancreas samples were homogenized with ice-cold 25 mM
Tris-HCl buffer (pH 7.5) using Ultra Turrax homogenizer
(IKA, Wilmington, NC, U.S.A.) for 4 min. The homogenates
were centrifugated at 14,000 rpm for 20 min. The super-
natants were collected and the protein concentrations were
mearsured by the method of Lowry et al. (27). Protein extracts
(20  g/lane) were diluted in sodium dodecylsulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) loading buffer
in a ratio of 1:1 and heated at 100℃ for 5 min. Samples
were electrophoresed on 10% Tris-Glycine polyacrylamide
gel in 1× Tris-glycine SDS buffer at room temperature. After
electrophoresis, the gel was transferred to 0.45  m Hybond-
P membrane for 2 hr at 4℃. The  membrane was blocked
in 5% blocking solution (5% skim milk, 1× PBS [pH
7.4], and 0.1% Tween20) for 1 hr and incubated for 1 hr
with IgG polyclonal rabbit antibody against iNOS (anti-
iNOS 1:2,000; Affinity, Golden, CO, U.S.A.). Blots were
washed four times with washing solution (1× PBS [pH7.4],
and 0.1% Tween20) and incubated for 1 hr with secondary
antibody (1:1,500 dilution), peroxidased, labeled anti-rab-
bit immunoglobulin G. Labeled proteins were visualized by
ECL kit (Ammersham Life Science, Buckinghamshire, U.K.)
by following the manufacture’s suggested protocol, followed
by autoradiography.
Tissue Water Content 
Fragments of pancreas were blotted dry and weighed to
determine tissue wet weight. This tissue was then dessicated
by overnight incubation at 80℃ and reweighed to deter-
mine tissue dry weight. Pancreas water content was calcu-
lated as the difference between wet and dry weights and
expressed as a percentage of wet weight.
Histologic Grading 
Pancreatic tissue was fixed in 20% formalin, embedded
in paraffin wax, and sectioned into 5  m slices. The tissue
was stained with hematoxylin and eosin. Histologic assess-
ment was performed on all tissue specimens of all parts. Mor-
phological changes were evaluated in a blind manner by two
independent pathologists. The histologic grading of inflam-
matory cell infiltration was carried out with reference to a
scale ranging from 0 to 3 (minimal to maximal, respective-522 S.H. Um, Y.D. Kwon, C.D. Kim, et al.
ly). By contrast, the grading of necrosis and vacuolization
was based on the percentage contained in the examined area.
The samples were graded as follows: absence of lesion=0;
involvement of 1-10%=1; 11-25%=2; 26-50%=3; >50%=4.
Data Analysis 
All values were expressed as means±SEM. Differences
between groups were evaluated by one-way ANOVA and
Mann-Whitney rank-sum test. Statistical significance was
assumed for pvalue <0.05.
RESULTS
iNOS expression
Western blot analysis showed expression of iNOS in pan-
creata from the pancreatitis group. In contrast, no expression
of iNOS was detected in the control group (Fig. 1).
Effect of NOS Inhibitor or Substrate on Serum Amy-
lase and Plasma NOx Activity
The serum amylase concentration was significantly in-
creased in group II, which received cerulein, as compared
with the control group. In the group III, treated with L-
NAME, level of amylase was significantly reduced to 3,900
±420 U/L, 50% of that in the cerulein group (p<0.01). In
group IV, treated with coinfusion of L-NAME and L-argi-
nine, serum amylase level did not change significantly as
compared with the cerulein group (Fig. 2).
As shown in Fig. 3, the plasma NOx concentration in the
cerulein group was significantly increased compared to that
in the control group, from 5.3±2.3 to 41.2±3.8 mol/L.
On the other hand, a significant decrease in the plasma NOx
level was observed in group III compared with that of group
II (p<0.01). However, the combined administration of L-
NAME and L-arginine (group IV) reversed the effect of L-
NAME on plasma NOx level.
Effect of NOS Inhibition or Substrate on Pancreas
Water Content
The pancreatic water content of rats receiving cerulein alone
(group II) was significantly greater than that of the control
group (86.6±2.3 to 73.9±2.1%, p<0.05). The pancreatic
water content in group III (79.4±3.9%) was significantly less
than that of the cerulein group (p<0.05). However, no signifi-
cant changes were observed in group IV (84.7±1.8%).
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Fig. 2. Effect of NOS inhibitor or substrate on serum amylase acti-
vities in cerulein (CER)-induced pancreatitis. Serum amylase level
was significantly decreased in group treated with L-NAME. Com-
bined administration of L-NAME and L-arginine reversed the effect
of L-NAME on serum amylase. Data represent the mean ±SEM.
*p<0.001 vs. control; **p<0.01 vs. Cerulein group receiving injec-
tion cerulein.
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Fig. 3. Effect of NOS inhibitor or substrate on plasma NOx level in
cerulein (CER)-induced pancreatitis. Plasma NOx activities was
significantly decreased in group treated with L-NAME. Combined
administration of L-NAME and L-arginine reversed the effect of
L-NAME on plasma NOx level. Data represent the mean ±SEM.
*p<0.001 vs. control; **p<0.01 vs. Cerulein group receiving injec-
tion of cerulein.
*
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Fig. 1. The expression of iNOS. Western blot analysis showed
expression of iNOS in pancreata from the pancreatitis group.
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Effect of NOS Inhibitor or Substrate on Histological
Changes of Pancreas
The histological change of the pancreas is presented in the
Fig. 4 and 5. This histological examination of pancreata
from group II showed changes compatible with an edema-
tous form of acute pancreatitis such as interstitial edema,
inflammatory cell infiltration, acinar cell vacuolization and
minimal evidence of cell necrosis. Group III, which received
L-NAME, showed a significant reduction of inflammatory
cell infiltrations such as neutrophil compared to group II
(p<0.01). Vacuolization of acinar cells or necrosis were also
significantly decreased in group III (p<0.01). However, group
IV, treated with both L-NAME and L-arginine, showed no
significant histological changes when compared with group II.
DISCUSSION
It is generally believed that a very early event in the evo-
Fig. 4. Effect NOS inhibitor or substrate on pancreatitis in rats. (A) Pancreas from control rat. (B) Pancreas from rat injected with cerulein
alone, showing extensive acinar cell vacuolization, interstitial edema and inflammatory cell infiltration. (C) Pancreas from rat treated with
L-NAME showing marked reduction in acinar cell vacuolization, edema and inflammatory cell infiltration. (D) Pancreas from rat treated
with L-NAME and L-arginine showing similar finding as B (H&E stain, ×400).
A B
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lution of acute pancreatitis is the release of proinflammatory
cytokines including tumor necrosis factor- , interleukin (IL)-
6 and IL-8 from the inflamed pancreas. Levels of these cyto-
kines from patients with acute pancreatits correlate with the
severity of the disease (2-4). The proinflammatory cytokines
activate the production of the iNOS, resulting in overpro-
duction of NO, which acts as a key final cellular and inter-
cellular mediator (5, 9-11). Recently, Al-Mufti et al. (7) have
shown in an experimental acute pancreatitis that there is
substantial induction of iNOS with down-regulation of
constitutive NOS (cNOS) in the pancreas, resulting in an
increase in total pancreatic NOS activity together with the
production of tissue peroxynitrate. At the same time point,
they observed that the increased expression of iNOS was
mainly localized within vascular smooth muscle cells, with
positive perivascular staining for nitrotyrosine, marker for
peroxynitrite induced oxidative tissue damage. Taken togeth-
er, the above findings suggest that induction of iNOS and
the subsequent production of NO contribute to the patho-
physiology of acute pancreatitis.
To investigate the pathophysiologic role of NO, a direct
modulation of the NO pathway by application of either en-
dogenous NOS inhibitors or NO donors was chosen in animal
models of acute pancreatitis (14-25). However, controversial
results were obtained as to whether the effects of enhanced NO
generation are positive, negative, or negligible with respect
to the development of local and systemic complications in the
course of the disease. These differing results could result from
different models of pancreatitis, or may be attributable to dif-
ferent drug regimens that achieve partial or complete inhibi-
tion of NOS. Recently, special iNOS gene deletion “knock-
out” mice have been used to characterize the impact of NO
form iNOS during acute pancreatitis (8, 28). However, these
animal studies also have yielded ambiguous evidence in sup-
port of the role of NO in pancreatitis.
In this study, we have shown that the administration of
supramaximal dose of cerulein induces iNOS expression in
pancreatic tissue, and significantly increased plasma concen-
tration of NO metabolites. Also, our observations confirmed
that overproduction of NO arising from the iNOS was asso-
ciated with the development of acute pancreatitis as shown
by marked hyperamylasemia, increased pancreas water con-
tent, and histologically extensive acinar cell vacuolization.
Our data confirm previous observations of enhanced iNOS
expression and increased NO metabolites during acute pan-
creatitis (7, 21, 24, 29, 30). Because the amount of NO pro-
duced by cNOS is too small to be reflected in the changes of
NO levels, the induction of iNOS, presumably in macro-
phages and vascular smooth cells, may be responsible for
the large release of NO in acute pancreatitis (7). Although
the pathologic roles of iNOS and enhanced NO production
in acute pancreatitis still remain controversial, many studies
provide compelling evidence that iNOS is, in part, respon-
sible for the activation of inflammatory cascade as well as
pancreatic damage (5, 7, 10-12). Excessive production of
NO contributes to the delayed vascular decompensation
and to the hyporeactivity of the vasculature to vasoconstric-
tor agents observed in several experimental models of circu-
latory shock (10, 31). There is evidence that some of the
cytotoxic effects of NO are due to the formation of per-
oxynitrate, a reactive oxidant formed by the rapid reaction of
NO with superoxide anions (32). Accumulation data sug-
gest that peroxynitrite may contribute to the tissue injury
in a number of pathophysiologic conditions associated with
inflammation and/or oxidant stress (33). Furthermore, Al-
mufti et al. (7) showed that iNOS induction and oxidative
tissue damage in the pancreas were associated with an increase
in systemic NO and arterial hypotension. Strong evidence
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Fig. 5. Effect of NOS inhibitor or substrate on histological changes in cerulein-induced pancreatitis. In group treated with L-NAME shows
significant reduction of inflammatory cell infiltration, vacuolization and necrosis. In group treated with concomitant administration of both
L-NAME and L-arginine fail to show any effect on pathologic score. Data represent the mean±SEM. *p<0.01 vs. Cerulein group receiv-
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suggests that iNOS-deficient mice exhibit resistance to the
acute pancreatitis induced by cerulein (8). These notions may
in part explain how cytotoxicity from NO may participate
in the pancreatic damage associated with acute pancreatitis
in this study. 
We showed that the administration of universal NOS
inhibitor, L-NAME reduced each of the parameters used to
quantify the severity of cerulein-induced pancreatitis (i.e.,
serum amylase, pancreas water content, and histologic para-
meter), whereas concomitant administration of both L-NAME
and NOS substrate, L-arginine fail to show any effect on
injury parameters. Further, our study has shown that plasma
concentration of NO metabolites after the administration of
L-NAME significantly decreased. This effect was reversed
by combined administration of both L-NAME and L-argi-
nine. These results indicate that NO, and/or its reaction
products, damage pancreas tissue and that L-NAME could
confer some protection against the development of acute
experimental pancreatitis. These results are similar to those
generated other studies: administration of NG-nitro-L-argi-
nine (L-NNA), NOS inhibitor inhibited the elevation of
serum NOx in cerulein-induced pancreatitis in mice pre-
treated with lipopolysacharide (21). L-NAME, competitive
NOS inhibitor, has been shown to prevent lung injury in
acute pancreatitis model (24). Further, animal studies also
have documented that the administration of a selective iNOS
inhibitor reduces bacterial translocation in acute pancreatitis
and appears to have ameliorated the course of disease (25).
Therefore, inhibition of NOS had favorable effects on pan-
creatitis which is complicated by the condition in which
iNOS is expressed to produce excessive amounts of NO.
On the contrary, several investigations of acute experimen-
tal pancreatitis have shown that L-arginine reduced pancre-
atic edema formation and intrapancreatic trypsinogen acti-
vation, whereas L-NNA or L-NAME exacerbated the sever-
ity of pancreatitis (14-19). These studies have supported the
view that general blockade of NOS might affect cNOS and
cNOS blockade eliminates the beneficial effects of NO such
as vasodilatation to keep blood flow and reduction in leuko-
cyte adhesion. General blockade of NOS by universal inhi-
bitors such as L-NAME and L-NNA in vivo may exhibit
contrasting effects in organ function, depending on the pre-
dominant pathway or cell function that is disrupted, and on
the alternative activation of compensatory mechanism (10).
The possible effects of NOS inhibitor such as vasoconstriction,
increased blood pressure, protection against NO-mediated
tissue damage, enhanced platelet aggregation and enhanced
leukocyte accumulation, may be beneficial or detrimental
on pancreas inflammation. In an experimental pancreatitis,
increased iNOS activity plus down-regulation in cNOS activ-
ity and reduced mean arterial blood pressure have been report-
ed (7). In our study, administration of NOS inhibitor signif-
icantly reduced plasma NO level and pancreas injury in this
pancreatitis model. Therefore, these observations suggested
that general blockade of NOS may eliminate the harmful
effects of NO rather than diminishing its beneficial effects.
Consequently, L-NAME might affect iNOS and inhibit
excessive NO production by iNOS that might damage pan-
creas tissue. To further clarify the significance of iNOS in
acute pancreatitis, additional experiments with selective
iNOS inhibitor using the pancreatitis model, isolated per-
fused pancreas, should be considered.
In conclusion, we have shown that NO excessively pro-
duced via iNOS was involved in cerulein-induced pancre-
atitis. We have also demonstrated that L-NAME, universal
NOS inhibitor, attenuated the severity of pancreatic dam-
age associated with acute pancreatitis. The attenuation effect
of L-NAME may be attributable, in part, to a reduction of
plasma NO levels. We would conclude that an enhanced
formation of NO by iNOS plays an important role in the
development of acute pancreatitis, and inhibition of NO pro-
duction has a beneficial effect in reducing pancreatic inflam-
mation.
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